Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.12 USD | +1.98% | +6.74% | -15.57% |
Financials (USD)
Sales 2024 * | 116M | Sales 2025 * | 137M | Capitalization | 203M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | -26M | EV / Sales 2024 * | 1.65 x |
Net cash position 2024 * | 12.67M | Net cash position 2025 * | 14.68M | EV / Sales 2025 * | 1.38 x |
P/E ratio 2024 * |
-4.91
x | P/E ratio 2025 * |
-7.87
x | Employees | 330 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.36% |
Latest transcript on Akoya Biosciences, Inc.
1 day | +1.98% | ||
1 week | +6.74% | ||
Current month | +7.85% | ||
1 month | -5.50% | ||
3 months | -30.87% | ||
6 months | +8.42% | ||
Current year | -15.57% |
Managers | Title | Age | Since |
---|---|---|---|
Brian McKelligon
CEO | Chief Executive Officer | 55 | 17-06-30 |
Johnny Ek
DFI | Director of Finance/CFO | 48 | 23-03-19 |
Pascal Bamford
CTO | Chief Tech/Sci/R&D Officer | - | 21-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Shepler
CHM | Chairman | 67 | 15-10-31 |
Myla Lai-Goldman
BRD | Director/Board Member | 66 | 21-09-15 |
Director/Board Member | 67 | 19-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +8.20% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 4.12 | +1.98% | 93,323 |
24-05-03 | 4.04 | +1.25% | 141,995 |
24-05-02 | 3.99 | +0.76% | 67,365 |
24-05-01 | 3.96 | +3.66% | 114,557 |
24-04-30 | 3.82 | -1.04% | 117,398 |
Delayed Quote Nasdaq, May 06, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.57% | 203M | |
+8.06% | 219B | |
+6.94% | 183B | |
+13.54% | 136B | |
-0.27% | 63.07B | |
+11.59% | 51.28B | |
+7.76% | 52.55B | |
+1.14% | 41.21B | |
+3.21% | 36.43B | |
+26.11% | 31.87B |
- Stock Market
- Equities
- AKYA Stock